Sunday, September 13, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

View original at finance.yahoo.com
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Olema Oncology On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Olema is on-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial

    60% confidence

  • 2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens

    60% confidence

  • Transformation into a fully-integrated oncology company is underway in preparation for the Company's first potential commercial launch in late 2027

    60% confidence

  • The November 2025 public offering enables funding operations through numerous expected value-creating events with palazestrant

    60% confidence

  • Initial clinical results from OP-3136 are anticipated in Q2 2026

    60% confidence

  • Palazestrant has potential as the combination endocrine therapy of choice in the metastatic setting

    60% confidence

  • Commercial launch preparations are underway for a potential approval in late 2027

    60% confidence

  • Top-line data from OPERA-01 is expected in the fall of 2026

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com